还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

$ x9 o* z9 l! q                               
登录/注册后可看大图

4 O/ K. h& ^  a+ n请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

' R  T5 m/ H5 s; T5 F可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


; }7 z' x8 I! p! C" {4 C% s& CSub-category:
Molecular Targets
1 S" B2 V* s0 j/ u! \5 x7 O
3 r, B% ~4 a8 P7 q, t9 L
0 B- G6 D5 V" u+ Y$ K/ Q/ S; tCategory:
Tumor Biology
$ \- v5 G/ `" K+ k& [% Z! h  _
# D9 @5 D8 X4 u3 x, D2 F9 e% @! {
Meeting:
+ q& D& t( @. b* x! `0 g2011 ASCO Annual Meeting
" A1 a$ u4 H# N* D

Session Type and Session Title:
Poster Discussion Session, Tumor Biology

, W+ E! }- \' T: o/ O" _
/ Q: a2 U* D$ d, x; j: @Abstract No:
10517
7 t9 T. O% }: K

Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
/ ~- @! I/ o' z, g

Author(s):
7 Q+ f  P' F5 tJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

9 q- Y4 }1 u, _0 i: K0 n# `5 D

/ o$ m& m. r% L4 i; hAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

$ }: V5 h8 E$ f0 R- q( \* B; MAbstract Disclosures

8 q2 q% ^6 M) ~% A+ R! ]Abstract:

9 M& l6 I( {, w: C- c3 \4 K, ?1 K* u
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

2 A/ n+ v" M- x% ~/ {- T. C2 p

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

5 M2 O* G* x, |+ ^1 E/ \易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

, l- U2 R" U8 `6 d平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

. G' i# k1 s  Y2 m- |: }& m现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊